Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
BROOKLYN, N.Y.–(BUSINESS WIRE)–Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-enabled…
Getting Value From AI Takes More Than Buying The Tools
Cerence AI and Geely Advance Human-Machine Interaction Through Robotics Technology Services Partnership